Skip to content

A study for comparing Panchasama Churna and Devdarvyadi Churna in the treatment of Rheumatoid Arthritis (Amavata).

Comparative Clinical Evaluation of Panchasama Churna and Devdarvyadi Churna in Amavata (Rheumatoid Arthritis) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112181
Enrollment
30
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M049- Autoinflammatory syndrome, unspecified

Interventions

None listed

Sponsors

Vijaylaxmi Singh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of Rheumatoid arthritis with features mentioned in subjective parameters. The patients between the age group of 25 to 55 years of age. Patients having classical features of Amavata like Angamarda, Aruchi ,Trishna, Hrillasa, Alasya, Gaurava, Jwara, Shoola, Shotha. Patient with RA who has stopped their medicine more than 2 months Patients must fulfill the criteria for rheumatoid arthritis outlined by the 2010 ACR (American College of Rheumatology) and EULAR European League Against Rheumatism.

Exclusion criteria

Exclusion criteria: Patients younger than 25 or older than 55 years. Patients with severe crippling bone deformities. Patients who already diagnosed with Rheumatoid arthritis in chronic condition and on allopathy medicine 2 months Patients diagnosed with other types of arthropathy such as gout or ankylosing spondylitis. Patients with major systemic illness like Diabetes mellitus , Nephritis , Renal Failure , Hepatitis , Congestive heart failure , Hypertension , Cirrhosis of liver etc.

Design outcomes

Primary

MeasureTime frame
1.Pain in joints 2.Swelling in joints 3.Stiffness of the joints 4.Tenderness of jointsTimepoint: The assessment will be done at the baseline before the starting of trial. The follow up will be done at 2nd week, 4th week, 6th week and at the 8th week after the commencement of the trial.

Secondary

MeasureTime frame
1.Joint involvement 2.Serology 3.Acute phase reactantTimepoint: On 1st day of treatment and last day of treatment

Countries

India

Contacts

Public ContactDr Charu Sharma

Quadra Institute Of Ayurveda And Hospital

charu22jan@gmail.com7060398172

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026